pre-IPO PHARMA

COMPANY OVERVIEW

Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises. Tevogen’s leadership believes that accessible personalized immunotherapies are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation in the post-pandemic world.


LOCATION


THERAPEUTIC AREAS


WEBSITE

None


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


Jul 12, 2023

Tevogen Bio Welcomes Victor Sordillo, Renowned Global Safety Management Expert, to its Board of Directors


May 22, 2023

Tevogen Bio will Present Positive Proof-of-Concept Trial Findings at the 5th Annual Allogeneic Cell Therapies Summit in Boston, MA


May 11, 2023

Tevogen Bio Expresses Gratitude as CEO is Named Recipient of Boy Scouts of America Distinguished Citizen Award


Apr 26, 2023

Tevogen Bio CSO to Discuss Investigational T Cell Therapy at NOLA Conference Focused on Long COVID and COVID-Related Cancer Risk, Alongside Leading Oncology Experts


Jan 23, 2023

Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company’s Precision Cell Therapy Platform


For More Press Releases


Google Analytics Alternative